C4 Therapeutics (CCCC) PT Raised to $13 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $3.06 -4.67%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Stifel analyst Bradley Canino raised the price target on C4 Therapeutics (NASDAQ: CCCC) to $13.00 (from $12.00) while maintaining a Buy rating.
You May Also Be Interested In
- C4 Therapeutics to Participate in Upcoming November Investor Conferences
- Datadog (DDOG) PT Lowered to $285 at Rosenblatt
- Leidos Holdings (LDOS) PT Lowered to $138 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
